stockrow
Friday 6 November 2026
Export MYGN’s income statement to Excel — free account
Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024.
- Revenue
- −10.5%
- EPS
- +87.1%
- Free cash flow
- +43.9%
- Total debt
- +103.2%
Quarter to June 2026, against a year earlier
6.19
0.17
+2.82%
Follow MYGN
Alert me
Myriad Genetics, Inc. (MYGN) P/E ratio
Myriad Genetics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 785× (August 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 785×
Ten-year median
0.0×
Current reading's percentile
60
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. | n/m |
| BDSX Biodesix, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| OPK OPKO Health, Inc. compare | n/m |
| FRNM Freenome, Inc compare | n/m |
| XGN Exagen Inc. compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)